Meningococcal Vaccines Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

Description

Persistence Market Research has recently released a detailed report on the global meningococcal vaccines market. This report provides an in-depth evaluation of critical market dynamics, including drivers, trends, opportunities, and challenges, offering a thorough understanding of the market structure.

Key Insights:

Meningococcal Vaccines Market Size (2024E): USD 4322.73 Million
Projected Market Value (2031F): USD 7692.59 Million
Global Market Growth Rate (CAGR 2024 to 2031): 8.6%

Meningococcal Vaccines Market - Report Scope:

The meningococcal vaccines market is crucial for preventing infections caused by Neisseria meningitidis, including meningitis, meningococcemia, and septicemia. This market includes vaccines targeting various serogroups of the bacteria, with A, B, C, Y, and W-135 being the most common. The growing incidence of meningococcal disease, combined with increasing awareness and improved accessibility to vaccines, is driving the market's expansion.

Market Growth Drivers:

The global meningococcal vaccines market is driven by several key factors, including the increased incidence of meningococcal disease. Meningococcal meningitis, in particular, is highly contagious and can lead to severe complications or death if left untreated. The rising number of cases and the high mortality and morbidity rates associated with the disease are fueling the demand for vaccines. Additionally, increased awareness campaigns by governments, companies, and non-profit organizations are contributing to higher vaccination rates. These initiatives focus on educating the public and healthcare professionals about the importance of early detection and prevention through vaccination, thereby boosting the market. Another significant driver is the improved accessibility of meningococcal vaccines in underserved regions. Global organizations are working to make vaccines available in low-income countries, particularly in Africa, where the disease burden is high. These efforts, combined with companies' interest in entering these markets, are expected to support market growth.

Market Restraints:

Despite the promising growth prospects, the meningococcal vaccines market faces several challenges. One of the primary restraints is the limited supply of vaccines and the reliance on a few manufacturers. This issue is compounded by financial constraints in many countries, which limit their ability to procure vaccines, and by public unawareness, which reduces vaccination rates. Moreover, differential pricing strategies in developing countries can further restrict access to newly approved vaccines, limiting market penetration and growth potential.

Market Opportunities:

The meningococcal vaccines market presents substantial growth opportunities driven by ongoing efforts to increase vaccine coverage in underserved regions. Companies that successfully navigate the challenges of limited supply and pricing disparities can capitalize on the growing demand in these markets. Furthermore, continued investment in public awareness campaigns and partnerships with global health organizations are likely to enhance market growth.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the meningococcal vaccines market globally?
Which serogroups of meningococcal bacteria are most commonly targeted by vaccines?
How are global health initiatives influencing the competitive landscape of the meningococcal vaccines market?
Who are the key players in the meningococcal vaccines market, and what strategies are they employing to enhance their market presence?
What are the emerging trends and future prospects in the global meningococcal vaccines market?

Competitive Intelligence and Business Strategy:

Leading players in the global meningococcal vaccines market, including companies such as GlaxoSmithKline, Pfizer, Sanofi Pasteur, and Merck & Co., focus on innovation, strategic partnerships, and expanding their reach into underserved markets to gain a competitive edge. These companies invest in research and development to offer vaccines that target multiple serogroups and improve vaccine efficacy and accessibility. Collaborations with global health organizations and governments help to enhance vaccine distribution and coverage, particularly in low-income regions. Emphasis on public education and awareness campaigns drives market growth and strengthens market positioning in the dynamic meningococcal vaccines industry.

Key Companies Profiled:

Sanofi Pasteur Inc.
GlaxoSmithKline
Wyeth Pharmaceuticals

Meningococcal Vaccines Market Categorization

Meningococcal Vaccines Market by Product

Polysaccharide Vaccine
Conjugate Vaccine
Serogroup B Vaccine

Meningococcal Vaccines Market by Age Group

Infants (0-24 months)
Children
Adolescents and Young Adults
Adults

Meningococcal Vaccines Market by Distribution Channel

Institutional Sales
Retail Sales

Meningococcal Vaccines Market by Region

North America
Latin America
Europe
Asia Pacific
Middle East & Africa (MEA)

Product Code: PMRREP3640

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Product Innovation

4. Key Success Factors

4.1. Pipeline Analysis
4.2. Recent Product Launches
4.3. Promotional Strategies, by Manufacturers
4.4. Regulatory Scenario

5. Global Meningococcal Vaccine Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2031

5.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
5.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
- 5.2.1. Y-o-Y Growth Trend Analysis
- 5.2.2. Absolute $ Opportunity Analysis

6. Market Background

6.1. Macro-Economic Factors
- 6.1.1. Global Healthcare Spending Outlook
- 6.1.2. Global Pharmaceutical Outlook
- 6.1.3. Regional Healthcare Market Outlook
6.2. Forecast Factors - Relevance & Impact
6.3. Value Chain
6.4. Pipeline Analysis
6.5. Market Dynamics
- 6.5.1. Drivers
- 6.5.2. Restraints
- 6.5.3. Opportunity Analysis

7. Global Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031, by Product Type

7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2019-2023
7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product Type, 2024-2031
- 7.3.1. Meningococcal Polysaccharide Vaccine (MPSV4)
- 7.3.2. Meningococcal Conjugate Vaccine (MCV4)
- 7.3.3. Serogroup B Meningococcal Vaccine (MenB-FHpb/MenB-4C)
7.4. Market Attractiveness Analysis By Product Type

8. Global Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031, by Age Group

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Age Group, 2019-2023
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Age Group, 2024-2031
- 8.3.1. Infants (0-24 months)
- 8.3.2. Children
- 8.3.3. Adolescents and Young Adults
- 8.3.4. Adults
8.4. Market Attractiveness Analysis By Age Group

9. Global Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031, by Distribution Channel

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2031
- 9.3.1. Institutional Sales
  - 9.3.1.1. Hospitals
  - 9.3.1.2. Community Clinics
  - 9.3.1.3. Public Health Agencies
- 9.3.2. Retail Sales
  - 9.3.2.1. Retail Pharmacy
  - 9.3.2.2. Mail Order Pharmacy
9.4. Market Attractiveness Analysis By Distribution Channel

10. Global Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031, by Region

10.1. Introduction
10.2. Historical Market Size (US$ Mn) and Volume Analysis By Region, 2019-2023
10.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast By Region, 2024-2031
- 10.3.1. North America
- 10.3.2. Latin America
- 10.3.3. Europe
- 10.3.4. East Asia
- 10.3.5. South Asia
- 10.3.6. Oceania
- 10.3.7. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis By Region

11. North America Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031

11.1. Introduction
11.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
11.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2024-2031
- 11.3.1. By Country
  - 11.3.1.1. U.S.
  - 11.3.1.2. Canada
- 11.3.2. By Product Type
- 11.3.3. By Age Group
- 11.3.4. By Distribution Channel
11.4. Market Attractiveness Analysis
11.5. Market Trends
11.6. Key Market Participants - Intensity Mapping
11.7. Drivers and Restraints - Impact Analysis

12. Latin America Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031

12.1. Introduction
12.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
12.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2024-2031
- 12.3.1. By Country
  - 12.3.1.1. Brazil
  - 12.3.1.2. Mexico
  - 12.3.1.3. Rest of Latin America
- 12.3.2. By Product Type
- 12.3.3. By Age Group
- 12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.5. Market Trends
12.6. Key Market Participants - Intensity Mapping
12.7. Drivers and Restraints - Impact Analysis

13. Europe Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031

13.1. Introduction
13.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
13.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2024-2031
- 13.3.1. By Country
  - 13.3.1.1. Germany
  - 13.3.1.2. Italy
  - 13.3.1.3. France
  - 13.3.1.4. U.K.
  - 13.3.1.5. Spain
  - 13.3.1.6. BENELUX
  - 13.3.1.7. Russia
  - 13.3.1.8. Rest of Europe
- 13.3.2. By Product Type
- 13.3.3. By Age Group
- 13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis

14. South Asia Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031

14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
14.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2024-2031
- 14.4.1. By Country
  - 14.4.1.1. India
  - 14.4.1.2. Thailand
  - 14.4.1.3. Indonesia
  - 14.4.1.4. Malaysia
  - 14.4.1.5. Rest of South Asia
- 14.4.2. By Product Type
- 14.4.3. By Age Group
- 14.4.4. By Distribution Channel
14.5. Market Attractiveness Analysis
14.6. Market Trends
14.7. Key Market Participants - Intensity Mapping
14.8. Drivers and Restraints - Impact Analysis

15. East Asia Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031

15.1. Introduction
15.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
15.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2024-2031
- 15.3.1. By Country
  - 15.3.1.1. China
  - 15.3.1.2. Japan
  - 15.3.1.3. South Korea
- 15.3.2. By Product Type
- 15.3.3. By Age Group
- 15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis

16. Oceania Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031

16.1. Introduction
16.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
16.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2024-2031
- 16.3.1. By Country
  - 16.3.1.1. Australia
  - 16.3.1.2. New Zealand
- 16.3.2. By Product Type
- 16.3.3. By Age Group
- 16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis

17. Middle East and Africa Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031

17.1. Introduction
17.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2019-2023
17.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2024-2031
- 17.3.1. By Country
  - 17.3.1.1. GCC Countries
  - 17.3.1.2. Turkey
  - 17.3.1.3. Northern Africa
  - 17.3.1.4. South Africa
  - 17.3.1.5. Rest of Middle East and Africa
- 17.3.2. By Product Type
- 17.3.3. By Age Group
- 17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis

18. Emerging Countries Meningococcal Vaccine Market Analysis 2019-2023 and Forecast 2024-2031

18.1. Introduction
- 18.1.1. Market Value Proportion Analysis, By Key Countries
- 18.1.2. Global Vs. Country Growth Comparison
18.2. China Meningococcal Vaccine Market Analysis
- 18.2.1. Introduction
- 18.2.2. PEST Analysis
- 18.2.3. Market Value Proportion Analysis by Market Taxonomy
- 18.2.4. Market Volume (Mn Units) and Value (US$ Mn) Analysis and Forecast by Market Taxonomy
  - 18.2.4.1. By Product Type
  - 18.2.4.2. By Age Group
  - 18.2.4.3. By Distribution Channel
18.3. India Meningococcal Vaccine Market Analysis
- 18.3.1. Introduction
- 18.3.2. PEST Analysis
- 18.3.3. Market Value Proportion Analysis by Market Taxonomy
- 18.3.4. Market Volume (Mn Units) and Value (US$ Mn) Analysis and Forecast by Market Taxonomy
  - 18.3.4.1. By Product Type
  - 18.3.4.2. By Age Group
  - 18.3.4.3. By Distribution Channel
18.4. Brazil Meningococcal Vaccine Market Analysis
- 18.4.1. Introduction
- 18.4.2. PEST Analysis
- 18.4.3. Market Value Proportion Analysis by Market Taxonomy
- 18.4.4. Market Volume (Mn Units) and Value (US$ Mn) Analysis and Forecast by Market Taxonomy
  - 18.4.4.1. By Product Type
  - 18.4.4.2. By Age Group
  - 18.4.4.3. By Distribution Channel

19. Market Structure Analysis

19.1. Market Analysis by Tier of Companies (Meningococcal Vaccine)
19.2. Market Share Analysis of Top Players
19.3. Brand Share Analysis
19.4. Market Presence Analysis
- 19.4.1. By Regional footprint of Players
- 19.4.2. Product foot print by Players
- 19.4.3. Channel Foot Print by Players

20. Competition Analysis

20.1. Competition Dashboard
20.2. Pricing Analysis by Competition
20.3. Competition Benchmarking
20.4. Competition Deep Dive
- 20.4.1. Sanofi Pasteur Inc.
  - 20.4.1.1. Overview
  - 20.4.1.2. Product Portfolio
  - 20.4.1.3. Profitability by Market Segments (Product/Channel/Region)
  - 20.4.1.4. Sales Footprint
  - 20.4.1.5. Strategy Overview
    - 20.4.1.5.1. Marketing Strategy
    - 20.4.1.5.2. Product Strategy
    - 20.4.1.5.3. Channel Strategy
- 20.4.2. GlaxoSmithKline
  - 20.4.2.1. Overview
  - 20.4.2.2. Product Portfolio
  - 20.4.2.3. Profitability by Market Segments (Product/Channel/Region)
  - 20.4.2.4. Sales Footprint
  - 20.4.2.5. Strategy Overview
    - 20.4.2.5.1. Marketing Strategy
    - 20.4.2.5.2. Product Strategy
    - 20.4.2.5.3. Channel Strategy
- 20.4.3. Wyeth Pharmaceuticals
  - 20.4.3.1. Overview
  - 20.4.3.2. Product Portfolio
  - 20.4.3.3. Profitability by Market Segments (Product/Channel/Region)
  - 20.4.3.4. Sales Footprint
  - 20.4.3.5. Strategy Overview
    - 20.4.3.5.1. Marketing Strategy
    - 20.4.3.5.2. Product Strategy
    - 20.4.3.5.3. Channel Strategy